PANHEMATIN Dosing

Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.
PANHEMATIN is for intravenous use only. Dose is 1 to 4 mg/kg/day for 3-14 days based on the clinical signs.
Standard dose in clinical practice is 3 to 4 mg/kg/day.
Repeat dose in more severe cases no earlier than every 12 hours. Do not exceed 6 mg/kg in any 24-hour period.

PANHEMATIN Administration

Reconstitute PANHEMATIN by adding 48 mL of Sterile Water for Injection, USP.
Because PANHEMATIN contains no preservative and undergoes rapid chemical decomposition in solution, it must be reconstituted immediately before use.
Administer over a period of at least 30 minutes

PANHEMATIN Administration Video

View this step-by-step tutorial on how to administer PANHEMATIN to a patient with AIP, including dose calculations.

PANHEMATIN Administration Guide

Download this step-by-step guide to dosing, preparation, and infusion.

DOWNLOAD GUIDE

Ordering PANHEMATIN

How to order PANHEMATIN

To order PANHEMATIN in the US, contact either:

ASD Healthcare: phone: 1-800-746-6273 fax: 1-800-547-9413
email: asd.customerservice@asdhealthcare.com

Or your primary wholesaler

How supplied

PANHEMATIN is supplied as a sterile, lyophilized black powder in single dose dispensing vials (NDC 55292-702-54) in a carton (NDC 55292-702-55).

The vial stopper contains natural rubber latex.

Store lyophilized powder at 20-25°C (68-77°F).

Resources for Your Patients Help your patients access support

Indications And Usage

PANHEMATIN^® is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.

Limitations of Use

Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days).

Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.

Important Safety Information

Do not use in patients with known hypersensitivity to PANHEMATIN.

Phlebitis is possible. Utilize a large arm vein or a central venous catheter for administration to minimize the risk of phlebitis.

Elevated iron and serum ferritin may occur. Monitor iron and serum ferritin in patients receiving multiple administrations of PANHEMATIN.

PANHEMATIN has transient and mild anticoagulant effect. Avoid concurrent anticoagulant therapy.

Reversible renal shutdown has been observed with an excessive hematin dose (12.2 mg/kg in a single infusion). Strictly follow recommended dosage guidelines.

PANHEMATIN may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Most common adverse reactions in >1% of patients are headache, pyrexia, infusion site reactions, and phlebitis.

To report SUSPECTED ADVERSE EFFECTS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1800-FDA-1088 or www.fda.gov/medwatch.

Avoid CYP inducing drugs such as estrogens, barbituric acid derivatives and steroid metabolites which induce δ‑aminolevulinic acid synthetase 1 (ALAS1) through a feedback mechanism.

Download the FREE Family Discussion Guide and opt in to receive future communications from Recordati Rare Diseases. Fill out the form below.

PANHEMATIN Dosing